SEMMA Therapeutics Melton
<p>Jul 08, 2015 10:58 AM</p>
<p>
Doug Melton's company.</p>
<p>
March 18 2015: 44M funding led by MPM Capital series A with Fidel Biosci, ARCH Ventures and
Medtronic. and Novartis.</p>
<p>
Melton: Prof Hvd and Co-chiar of Dept of Stem Cell/ REgen Bio and NAS.</p>
<p>
Robt Millman managing direc of Semma... will be CEO.</p>
<p>
thru clinical proof in man.</p>
<p>
Isaac Kohlbeg Chief Tech Dev at Harvd.</p>
<p>
Semma combine cells with SOTA device.</p>
<p>
Nov 07, 2017 06:36 PM (this was Oct 2017) Felicia Pagliuca, PhD
co-founder and VP, cell bio R and D...</p>
<p>
Semma Therapeutics Meeting on the Mesa: 50M people inject themselves....
beta cells in islets of Langerhans...</p>
<p>
autoimmune: destruction...</p>
<p>
cadaveruc islets transplat has rxed thousands of pts.</p>
<p>
SC-islet = stem cell derived islet... shows a x-section...</p>
<p>
green = insulin in the imae; red is a key transcrip factor....</p>
<p>
v similar to normal naturla pancreas.... collab with Dr Melton at Hvd.</p>
<p>
great insulin secretion!!! see slide 8!!!
glucose stim insulin secretion....
natural islets (organ donor islet source level = 6)
SC-islets (cliical cell line = 10 !!!)</p>
<p>
process has been scaled to multi-liter bioreactors for manufac.</p>
<p>
DELIVERY:</p>
<p>
slide 9: use selective permeable membranes</p>
<p>
device encapsulation are main focus...</p>
<p>
providence Rhode Island site; new biomaterials....</p>
<p>
preclinical data pkg pre-clinical in animals</p>
<p>
shows 90 day result....</p>
<p>
shows rodent graph... glucose up to 600 when induce DM</p>
<p>
then show s90 day data... great control!!! mice with DM...</p>
<p>
minimal foreign body reacitn...</p>
<p>
proof of concept estblished; cadaveric;</p>
<p>
single arm open-label designs ....</p>
<p>
Eliz Stoner is Interim CEO Mang Direc MPM Captial</p>
<p>
prob 8 on team and</p>
<p>
Mark Fishman Chm of Novartis Res!!! NIBR...</p>
<p>
no cell killing within device....</p>
<p>
</p>
<p>
</p>
<p>
</p>
<p>
</p>
<p>
</p>